Fudan University Shanghai Cancer Center,
Welcome,         Profile    Billing    Logout  
 11 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shao, Zhi-Ming
NCT04403529: Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Recruiting
3
200
RoW
Traditional Chinese Medicine Formulation, "prescription for breast cancer" Traditional Chinese Medicine formulation, Placebo Formulation, Placebo granules contains 5% "prescription for breast cancer" Traditional Chinese Medicine formulation and 95% filler
Fudan University
Triple Negative Breast Cancer
05/24
05/24
BCTOP-T-M02, NCT05760378: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Recruiting
3
223
RoW
Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Fudan University
Triple-Negative Breast Cancer
01/25
01/27
NCT06913777: Neoadjuvant SNF Precision Therapy Phase III

Not yet recruiting
3
404
RoW
Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC)
Fudan University
Neoadjuvant Therapy
10/26
04/27
NCT05999149: A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Recruiting
3
424
RoW
Camrelizumab Plus Chemotherapy and Famitinib, camrelizumab+chemotherapy+Famitinib, Camrelizumab Plus Chemotherapy
Fudan University
TNBC - Triple-Negative Breast Cancer
08/25
08/27
BCTOP-T-M01, NCT05806060: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
3
192
RoW
VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), nab-paclitaxel, with maintenance of capecitabine, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1, VEGFR and TPC
Fudan University
Triple-Negative Breast Cancer
08/25
02/26
NCT05901428: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Recruiting
3
1736
RoW
Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide
Fudan University
Hormone Receptor Positive HER-2 Negative Breast Cancer
06/26
06/28
NCT05862064: PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Recruiting
3
606
RoW
epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
Fudan University
TNBC - Triple-Negative Breast Cancer
07/26
07/28
BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer

Recruiting
3
766
RoW
Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist
Fudan University
Breast Cancer
05/28
05/31
BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients

Recruiting
3
548
RoW
Antivascular therapy, Chemotherapy
Fudan University
Breast Cancer, Triple Negative Breast Cancer
05/29
05/31
ORCHID, NCT04296162: Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer

Active, not recruiting
2
178
RoW
Vinorelbine, Capecitabine, Trastuzumab
Fudan University
Breast Cancer
07/25
06/27
MULAN, NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Recruiting
2
319
RoW
SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi
Fudan University
Breast Cancer, Metastatic Cancer
05/23
04/25
NCT06516289: Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Recruiting
2
130
RoW
HRS-1167, Famitinib, Camrelizumab
Fudan University
BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer
06/26
06/27
ENIGMA, NCT05205200: Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer()-BCTOP-L-M02

Recruiting
2
338
RoW
SHR-1316, SHR6390, Nab paclitaxel, SERD, AI
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Tumor Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Cancer, Metastatic Cancer
02/25
08/26
IRIS, NCT04383275: Stage I HER2 Positive Invasive Breast Cancer De-escalation Study

Recruiting
2
356
RoW
capecitabine and trastuzumab, endocrine therapy and trastuzumab
Fudan University
Breast Cancer
05/25
05/27
BCTOP-L-M04, NCT05759572: Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Recruiting
2
145
RoW
Apatinib, Dalpiciclib, Fulvestrant/AI
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Tumor Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Cancer Metastatic
11/25
06/27
NCT05759546: PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Recruiting
2
200
RoW
Fluzoparib, Dalpiciclib, Fulvestrant/AI
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Tumor Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Cancer Metastatic
11/25
06/27
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
NCT05861271: Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Recruiting
2
1008
RoW
Capecitabine，Pyrotinib, Pyrotinib
Fudan University
Breast Cancer Stage I
07/26
07/28
NCT06503380: Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

Recruiting
N/A
1000
RoW
No intervenrion.
Fudan University
Hematological Toxicity, Targeted Therapy, Breast Cancer
07/26
06/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shao, Zhi-Ming
NCT04403529: Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Recruiting
3
200
RoW
Traditional Chinese Medicine Formulation, "prescription for breast cancer" Traditional Chinese Medicine formulation, Placebo Formulation, Placebo granules contains 5% "prescription for breast cancer" Traditional Chinese Medicine formulation and 95% filler
Fudan University
Triple Negative Breast Cancer
05/24
05/24
BCTOP-T-M02, NCT05760378: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Recruiting
3
223
RoW
Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin
Fudan University
Triple-Negative Breast Cancer
01/25
01/27
NCT06913777: Neoadjuvant SNF Precision Therapy Phase III

Not yet recruiting
3
404
RoW
Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib, Chemotherapy (wP-EC)
Fudan University
Neoadjuvant Therapy
10/26
04/27
NCT05999149: A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Recruiting
3
424
RoW
Camrelizumab Plus Chemotherapy and Famitinib, camrelizumab+chemotherapy+Famitinib, Camrelizumab Plus Chemotherapy
Fudan University
TNBC - Triple-Negative Breast Cancer
08/25
08/27
BCTOP-T-M01, NCT05806060: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
3
192
RoW
VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), nab-paclitaxel, with maintenance of capecitabine, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1, VEGFR and TPC
Fudan University
Triple-Negative Breast Cancer
08/25
02/26
NCT05901428: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Recruiting
3
1736
RoW
Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide
Fudan University
Hormone Receptor Positive HER-2 Negative Breast Cancer
06/26
06/28
NCT05862064: PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Recruiting
3
606
RoW
epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
Fudan University
TNBC - Triple-Negative Breast Cancer
07/26
07/28
BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer

Recruiting
3
766
RoW
Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist
Fudan University
Breast Cancer
05/28
05/31
BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients

Recruiting
3
548
RoW
Antivascular therapy, Chemotherapy
Fudan University
Breast Cancer, Triple Negative Breast Cancer
05/29
05/31
ORCHID, NCT04296162: Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer

Active, not recruiting
2
178
RoW
Vinorelbine, Capecitabine, Trastuzumab
Fudan University
Breast Cancer
07/25
06/27
MULAN, NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Recruiting
2
319
RoW
SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi
Fudan University
Breast Cancer, Metastatic Cancer
05/23
04/25
NCT06516289: Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Recruiting
2
130
RoW
HRS-1167, Famitinib, Camrelizumab
Fudan University
BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer
06/26
06/27
ENIGMA, NCT05205200: Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer()-BCTOP-L-M02

Recruiting
2
338
RoW
SHR-1316, SHR6390, Nab paclitaxel, SERD, AI
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Tumor Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Cancer, Metastatic Cancer
02/25
08/26
IRIS, NCT04383275: Stage I HER2 Positive Invasive Breast Cancer De-escalation Study

Recruiting
2
356
RoW
capecitabine and trastuzumab, endocrine therapy and trastuzumab
Fudan University
Breast Cancer
05/25
05/27
BCTOP-L-M04, NCT05759572: Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Recruiting
2
145
RoW
Apatinib, Dalpiciclib, Fulvestrant/AI
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Tumor Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Cancer Metastatic
11/25
06/27
NCT05759546: PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Recruiting
2
200
RoW
Fluzoparib, Dalpiciclib, Fulvestrant/AI
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Tumor Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Cancer Metastatic
11/25
06/27
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
NCT05861271: Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Recruiting
2
1008
RoW
Capecitabine，Pyrotinib, Pyrotinib
Fudan University
Breast Cancer Stage I
07/26
07/28
NCT06503380: Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

Recruiting
N/A
1000
RoW
No intervenrion.
Fudan University
Hematological Toxicity, Targeted Therapy, Breast Cancer
07/26
06/27

Download Options